Exploiting novel models of endocrine-resistant breast cancer to identify new therapeutic targets

被引：1
|
作者：
Soosainathan, Arany
Nikitorowicz-Buniak, Joanna
Pancholi, Sunil
Iravani, Marjan
Alexander, John
Haider, Syed
Johnston, Stephen R.
Dowsett, Mitchell
Martin, Lesley A.
Isacke, Clare M.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P4-02-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-02-05
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
    Guest, Stephanie K.
    Ribas, Ricardo
    Pancholi, Sunil
    Nikitorowicz-Buniak, Joanna
    Simigdala, Nikiana
    Dowsett, Mitch
    Johnston, Stephen R.
    Martin, Lesley-Ann
    PLOS ONE, 2016, 11 (06):
  • [42] A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer
    Trinh, X. B.
    Sas, L.
    Van Laere, S. J.
    Prove, A.
    Deleu, I.
    Rasschaert, M. A.
    Van de Velde, H.
    Vinken, P.
    Vermeulen, P. B.
    van Dam, P. A.
    Wojtasik, A.
    De Mesmaeker, P.
    Tjalma, W. A.
    Dirix, L. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer
    Xin, Lilan
    Wang, Chao
    Cheng, Yan
    Wang, Hongli
    Guo, Xinyi
    Deng, Xiaofei
    Deng, Xiangping
    Xie, Baohua
    Hu, Hankun
    Min, Chang
    Dong, Chune
    Zhou, Hai-Bing
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (11) : 8913 - 8931
  • [44] A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer
    Trinh, X. B.
    Sas, L.
    Van Laere, S. J.
    Prove, A.
    Deleu, I.
    Rasschaert, M.
    Van De Velde, H.
    Vinken, P.
    Vermeulen, P. B.
    Van Dam, P. A.
    Wojtasik, A.
    De Mesmaeker, P.
    Tjalma, W. A.
    Dirix, L. Y.
    ONCOLOGY REPORTS, 2012, 27 (03) : 657 - 663
  • [45] Breast Cancer: Novel Therapeutic Targets
    Yip, George W.
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2011, 6 (02) : 164 - 165
  • [46] Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells
    Chan, J. Y.
    LaPara, K.
    Yee, D.
    ONCOGENE, 2016, 35 (32) : 4235 - 4243
  • [47] Native top-down proteomics enables discovery in endocrine-resistant breast cancer
    Gomes, Fabio P.
    Durbin, Kenneth R.
    Schauer, Kevin
    Nwachukwu, Jerome C.
    R. Kobylski, Robin
    Njeri, Jacqline W.
    Seath, Ciaran P.
    Saviola, Anthony J.
    McClatchy, Daniel B.
    Diedrich, Jolene K.
    Garrett, Patrick T.
    Papa, Alexandra B.
    Ciolacu, Ianis
    Kelleher, Neil L.
    Nettles, Kendall W.
    Yates III, John R.
    NATURE CHEMICAL BIOLOGY, 2025,
  • [48] Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells
    J Yun
    A Pannuti
    I Espinoza
    H Zhu
    C Hicks
    X Zhu
    M Caskey
    P Rizzo
    G D'Souza
    K Backus
    M F Denning
    J Coon
    M Sun
    E H Bresnick
    C Osipo
    J Wu
    P R Strack
    D A Tonetti
    L Miele
    Oncogenesis, 2013, 2 : e60 - e60
  • [49] A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer
    Shweta R Nayak
    Emily Harrington
    David Boone
    Ryan Hartmaier
    Jian Chen
    Thushangi N. Pathiraja
    Kristine L. Cooper
    Jeffrey L. Fine
    Joseph Sanfilippo
    Nancy E. Davidson
    Adrian V. Lee
    David Dabbs
    Steffi Oesterreich
    Hormones and Cancer, 2015, 6 : 214 - 224
  • [50] COUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells
    Litchfield, Lacey M.
    Appana, Savitri N.
    Datta, Susmita
    Klinge, Carolyn M.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2014, 382 (01) : 358 - 367
12345